Govt clears Mylan's takeover of Jai Pharma

Image
Press Trust of India New Delhi
Last Updated : Nov 05 2015 | 9:32 PM IST
The government today approved the proposal of global pharma major Mylan to invest USD 750 million in its Indian arm to help it acquire Taparia family-owned Jai Pharma Ltd (JPL).
The decision was taken by the Union Cabinet chaired by Prime Minister Narendra Modi.
The Cabinet has "approved the proposal of the Department of Economic Affairs for increase in FDI up to USD 750 million in Mylan Laboratories Ltd (MLL) by Mylan Luxembourg and / or Mylan Group through subscription of equity shares and / or compulsorily convertible debentures for providing MLL part of the funds required for the acquisition of the entire share - holding of JPL post the demerger from its then shareholders (including Orizaba and resident Indian shareholders)," an official statement said.
With this approval, FDI of USD 750 million will be received in the country, it added.
The approval has been accorded subject to certain conditions.
As per those conditions, the company has to maintain the production level of consumables and NLEM (National List of Essential Medicines) drugs and their supply to the domestic market at the time of induction of FDI over the period of next five years at an absolute quantitative level.
Besides, R&D expenses have to be maintained in value terms for five years at an absolute quantitative level at the time of induction of FDI, it said.
Further, the company receiving FDI will continue to produce medicines under the NLEM for the domestic tariff areas at the level which would be the highest quantity of production in the previous three financial years for the next five years, it added.
The company will also be required to maintain the R&D expenditure at the maximum level incurred in any of the three financial years immediately preceding the year of induction of FDI. This absolute level should be maintained for the next five years, the statement said.
"Second leg of transaction involves infusion of fresh foreign funds by Mylan group for acquiring shares of M/s. Jai Pharma Ltd. The taxability of capital gains arising out of the said transaction shall be examined by the field formation," it added.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 05 2015 | 9:32 PM IST

Next Story